L iver is the major metabolic organ that plays a central role in regulating whole body cholesterol homeostasis. 1 Endogenously synthesized cholesterol, along with triglycerides (TG), is packaged into very low-density lipoproteins (VLDL) and secreted. After delivery of TG as a source of energy for the peripheral tissues and cholesterol for membrane and steroid synthesis, the cholesterol-rich and TG-poor lowdensity lipoprotein (LDL) delivers the cholesterol back to the liver. LDL-associated cholesterol in the form of cholesteryl esters (CEs) is hydrolyzed in the lysosome, and the released free cholesterol (FC) is re-esterified by acyl CoA cholesterol acyltransferase 2 and stored as CEs in lipid droplets. In addition, excess cholesterol from peripheral tissue, including artery wall-associated macrophage foam cells, is also returned to the liver via the high-density lipoproteins (HDL) by the process named reverse cholesterol transport (RCT). To gain access to the intracellular cholesterol pool, HDL-CEs must be hydrolyzed within hepatocytes, and this hydrolysis is thought to occur in the nonlysosomal compartment, presumably by a neutral CE hydrolase (CEH). 2,3 Therefore, hepatic CEH is required not only to release FC from the intracellular stores of CEs (generated by acyl CoA cholesterol acyltransferase 2-mediated esterification) but also to hydrolyze CEs delivered via selective uptake of HDL and represents the key enzyme required for releasing the pool of metabolically active FC from intracellular stores of CEs, providing the substrate for bile acid synthesis and for biliary secretion of cholesterol.
is not consistent with a role in HDL-CE hydrolysis. 7 Camarota et al 8 described the association of bile-salt-stimulated lipase or carboxyl ester lipase (CEL) with scavenger receptor BI (SR-BI) and suggested a role for this enzyme in HDL-CE hydrolysis; however, the observed increase in RCT in CEL −/− mice indicates a limited role of this enzyme in the hydrolysis of HDL-CEs. 9 Parathath et al 10 recently characterized carboxylesterase ES4 from rat liver as a hepatic CEH but its role in the hydrolysis of HDL-CEs has not been evaluated as yet.
We had earlier described purification, 11 characterization, and cloning of rat liver CEH, 12 a member of the carboxylesterase family, and established its role in hepatic cholesterol homeostasis. 13 Recently, we also cloned and characterized human liver CEH and demonstrated that transient overexpression of CEH increased bile acid synthesis and secretion from primary human hepatocytes. 14 Furthermore, adenovirusmediated overexpression of this enzyme enhanced cholesterol elimination by increasing the flux of cholesterol from macrophages to feces (in vivo RCT). 15 More importantly, SR-BI deficiency completely abolished CEH-mediated increase in in vivo RCT, demonstrating the requirement of functional SR-BI for CEH to channel HDL-derived CEs to bile and feces. 15 Because only a small portion (5% to 20%) of biliary cholesterol is derived from de novo synthesis, 16, 17 and the bulk is supplied by the hepatic uptake of lipoproteins, 18, 19 by enhancing the hydrolysis of lipoprotein-derived CEs, hepatic CEH regulates the removal of cholesterol from the body and should, therefore, be antiatherogenic. In the present study, we examined the hypothesis that deficiency of hepatic CEH will decrease cholesterol elimination from the body and will, therefore, increase diet-induced atherosclerosis. The mouse homolog of human CEH is carboxylesterase-3 or Ces3, and we developed mice with liver-specific deficiency of Ces3 and examined the development of Western diet-induced atherosclerosis in these mice in low density lipoprotein receptor knock out (LDLR −/− ) background. The data presented herein show that hepatic Ces3 deficiency increases atherosclerosis and decreased fecal elimination of cholesterol as FC or bile acids is likely the underlying mechanism.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Development of Liver-Specific Ces3 Knockout (Ces3-LKO) Mice
Total RNA from multiple tissues was used to determine the expression of Ces3 in wild-type and liver-Specific Ces3 Knockout (Ces3-LKO) mice. Consistent with the liver-specific Cre recombinase expression in Alb-Cre transgenic mice, Ces3 expression was reduced by >95% in the liver, and no decrease was noted in other tissues tested ( Figure 1A ). Ces3 belongs to the carboxylesterase family, and several members of this family are expressed in the liver. To evaluate the effects, if any, on the expression of other carboxylesterases by Ces3 deficiency, expression of indicated carboxylesterases was also monitored. Other than a slight decrease in the expression of esterase 1, no differences were noted in the expression of other genes ( Figure 1B To determine the potential effects of Ces3 deficiency in affecting genes involved in maintaining hepatic cholesterol homeostasis, expression of HMGCR, acyl CoA cholesterol acyltransferase 2, Ldlr, CYP7A1, and SR-BI was assessed. Although a nonsignificant decrease in the expression of CYP7A1 was observed, there was no change in the expression of other genes ( Figure IA in the online-only Data Supplement).
Because FC released as a result of Ces3-mediated CE hydrolysis can either be secreted directly into bile via the FC transporter AbcG5/G8 or be converted into bile acids before secretion via bile acid transporter, expression of these transporters was evaluated. Ces3 deficiency did not affect the expression of these transporters ( Figure IB in the online-only Data Supplement). No change was also noted in phospholipid transporter multiple drug resistance protein 2.
Ces3-LKO mice were crossed into LDLR −/− background for all the subsequent studies. 
Hepatic Ces3 Deficiency Did Not Affect Liver Function Tests
Fasting plasma from Western-diet-fed LDLR −/− and LDLR −/− Ces-LKO mice was analyzed for aspartate aminotransferase, alanine aminotransferase, and bilirubin to evaluate the effects of Ces3 deficiency on liver function/toxicity. There was no significant difference in levels of these parameters ( Figure II in the online-only Data Supplement), indicating that Ces3 deficiency did not result in hepatic toxicity.
Hepatic Ces3 Deficiency Did Not Alter Hepatic Lipid Accumulation
Ces3 catalyzes the hydrolysis of hepatic CE as well as TG, and, to determine the effects of Ces3 deficiency on hepatic lipid levels, total lipids extracted from livers from Westerndiet-fed LDLR −/− and LDLR −/− Ces3-LKO mice were analyzed for total cholesterol, FC, CE, and TG levels. No significant differences were noted in hepatic lipids ( Figure 2A ). However, comparison between sexes showed that there is a significant increase in total cholesterol and CEs in female mice in both LDLR −/− as well as in LDLR −/− Ces3-LKO mice ( Figure IIIA in the online-only Data Supplement).
Hepatic Ces3 Deficiency Did Not Alter Cholesterol Levels of Plasma Lipoproteins
Fasting plasma from Western-diet-fed LDLR −/− and LDLR −/− Ces3-LKO mice was collected, and cholesterol distribution between VLDL, LDL, and HDL was determined. Hepatic Ces3 deficiency did not alter the cholesterol content of plasma lipoproteins ( Figure 2B ). However, comparison of percentage distribution of total plasma cholesterol between VLDL, LDL, and HDL between sexes showed a significantly higher percentage of cholesterol associated with VLDL in female mice of both genotypes ( Figure IIIB in the onlineonly Data Supplement). In contrast, percentage of total plasma cholesterol associated with LDL was higher in males of both genotypes.
Western-Diet Feeding Did Not Affect the Expression of Genes Involved in Hepatic Cholesterol Homeostasis
Total liver RNA from Western-diet-fed LDLR −/− and LDLR −/− Ces3-LKO mice was analyzed for the expression of other members of the carboxylesterase family and other potential hepatic CEHs. As shown in Figure IV in the onlineonly Data Supplement and similar to the absence of any significant changes in the expression of these genes in chow-fed mice, Western-diet feeding did not affect the expression of these genes in LDLR −/− Ces3-LKO mice. Similarly, no significant change was observed in the expression of genes involved in hepatic cholesterol homeostasis and cholesterol/bile acid transport ( Figure V in the online-only Data Supplement)
Hepatic Ces3 Deficiency Increased Atherosclerosis
Western-diet-induced atherosclerosis was monitored in LDLR −/− and LDLR −/− Ces3-LKO mice after 16 weeks of feeding. No mortality or morbidity was observed in mice with either genotype. The percentage area of aorta covered with atherosclerotic lesions was determined by en face analyses, and Figure 3 shows representative images of aortas obtained from LDLR −/− and LDLR −/− Ces3-LKO mice (males, Figure  3A and females, Figure 3B ). Although very few lesions were noticeable in the thoracic and abdominal aorta, as expected with this mouse model, the aortic arch displayed the most profound lesions. Although an increase in the atherosclerotic lesion area was observed in the aortic arch in LDLR −/− Ces3-LKO males, this increase was more pronounced in corresponding female mice. The quantification of the surface area occupied by atherosclerotic lesions is shown in Figure 4A . Compared with LDLR −/− mice, liver-specific Ces3 deficiency in LDLR −/− Ces3-LKO mice led to a significant increase in the total area occupied by the lesions in the aortic arch. The magnitude of this increase was higher in females (50.76±8.66%) compared with males (26.44±7.66%; Figure 4 ). Total area occupied by the lesions in the entire aorta was also determined, and liver-specific Ces3 deficiency significantly increased the total area occupied by atherosclerotic lesions, and once again the magnitude of this increase was higher in female mice. An overall effect of genotype on total (P=0.0012) and aortic arch (P=0.0008) lesion area was detected by ANOVA. Effects of sex and sex-genotype interactions were not detected ( Table I in the online-only Data Supplement).
Aortic cholesterol content was also determined and used as another measure of the development of atherosclerosis. As shown in Figure 4B and consistent with en face analyses of the atherosclerotic lesion, Ces3 deficiency resulted in significant increase in total cholesterol, FC, and CE content of the aorta. Taken together, these findings indicate that liver-specific Ces3 deficiency increases diet-induced atherosclerosis in LDLR −/− mice. Similar to the observed differences in lesion area, significant overall effect of the genotype was also noted in total (P=0.0039), free (P=0.0011), and esterified cholesterol (P=0.0192) without any significant sex-genotype interactions ( Table I in Aortic sinus lesions were compared to determine whether liver-specific Ces3 deficiency altered lesion morphology or affected lesion area at this anatomic site. Figure VIA in the online-only Data Supplement shows representative images. Total lesion area and percentage of acellular or the necrotic area was quantified, and no significant differences were noted in either of these parameters between the 2 genotypes in either sex ( Figure VIB in the online-only Data Supplement).
Hepatic Ces3 Deficiency Decreases Removal of HDL-Associated Cholesterol in Feces
FC removed from peripheral tissues, including artery wallassociated macrophage foam cells, is carried back to the liver as CEs in the HDL particle. CEs delivered to the liver by HDL need to be hydrolyzed to release FC either for direct secretion into the bile or for conversion into bile acids that are also secreted into bile, and we have demonstrated earlier that adenovirus-mediated overexpression of CEH enhances secretion of bile acids into the feces. 15 Fecal excretion of FC or bile acids represents the only route for removal of cholesterol from the body and is, therefore, an antiatherogenic process. To examine whether hepatic Ces3 deficiency-mediated reduction in removal of cholesterol in feces (either as FC or as bile acids) represents a potential mechanism for the observed increase in atherosclerosis in LDLR −/− Ces3-LKO mice, movement of radiolabeled cholesterol from HDL-CEs to FC and bile acids in feces was monitored. There was no significant difference in radioactivity associated with plasma or liver at the end of 48 hours ( Figure 5A ). Ces3 deficiency led to a significant decrease in fecal sterols (FC and bile acids) measured as the percentage of injected radioactive HDL-CEs ( Figure  5B ; P=0.0391 and 0.0023, respectively). Total fecal bile acids as well as cholesterol levels were also monitored, and, as shown in Figure 5C , consistent with decreased flux of HDL-CEs, there was a significant reduction in total fecal bile acids (P=0.0004) and FC (P=0.0001) in LDLR −/− Ces3-LKO mice. These data demonstrate that Ces3-mediated HDL-CE hydrolysis is required for conversion to bile acids and FC for the subsequent removal from the body in the feces.
To directly test that Ces deficiency reduces the hydrolysis of HDL-CEs, accumulation of FC in primary hepatocytes was monitored. Significant reduction (P=0.01) in intracellular FC was observed in primary hepatocytes isolated from LDLR −/− Ces3-LKO mice compared with LDLR −/− controls ( Figure VIIA To evaluate whether there is decreased bile acid secretion in vivo, gall bladder bile was collected from Westerndiet-fed LDLR −/− and LDLR −/− Ces3-LKO mice and analyzed. Bile acid levels normalized to phospholipid content are shown in Figure 6A . A significant decrease in bile acid levels was observed in LDLR −/− Ces3-LKO mice, indicating that decreased removal of cholesterol as bile acids represents the potential underlying mechanism for the observed increase in atherosclerosis. Total biliary cholesterol levels remained unchanged in Ces3-deficient mice ( Figure 6B ).
Discussion
Removal of biliary cholesterol and bile acids in the feces is the only mechanism for elimination of cholesterol from the body and is, therefore, antiatherogenic. Because bulk of the biliary cholesterol is derived from lipoproteins taken up by liver (de novo synthesized cholesterol contributes only 5% to 20% of biliary cholesterol) intracellular hydrolysis of endogenously synthesized CEs (from FC released after lysosomal hydrolysis of LDL-CEs) or CEs delivered by selective uptake from HDL via SR-BI is essential for this process. The data presented herein show for the first time that deficiency of hepatic CEH, Ces3, results in decreased movement of cholesterol from HDL-CEs to feces, resulting in increased diet-induced atherosclerosis in LDLR −/− Ces3-LKO mice. However, liverspecific Ces3 deficiency did not lead to significant changes plasma or hepatic lipids. This apparent lack of correlation between plasma lipids and development of atherosclerosis is consistent with the observed increase in atherosclerosis without altered plasma lipoprotein profiles in several other mouse Total radioactivity (dpm) of [ 3 H]-cholesterol was determined, and data (mean±SD; n=3) are presented as percentage of the total dpm injected. A, Radioactivity associated with plasma and liver homogenates was determined and normalized to 1 mL or 1 g wet weight, respectively. B, Radioactivity associated with fecal bile acids and free cholesterol (FC) was determined after extraction of dried feces and normalized to weight of total feces. C, Total bile acids and cholesterol were extracted from feces and analyzed as described under Methods. Data were normalized to dry weight of feces/d and presented as mean±SD, n=6. The effects of genotype (or Ces3 deficiency) on flux of [ 3 H] cholesterol from HDL to fecal FC and bile acids as well as total fecal sterol excretion were determined to be statistically significant, and individual probability values are included in the Table I in [20] [21] [22] and underscores the importance of enhancing cholesterol elimination from the body rather than altering plasma lipids alone as an antiatherogenic strategy. It is noteworthy that although a significant decrease in dyslipidemia was noted, there was no change in the development of atherosclerosis in Xbp1-deficient ApoE −/− mice. 23 Although formation of CE-laden macrophage foam cells is the key step in the development of arterial plaques, extracellular acceptor (eg, ApoA1 or HDL)-mediated removal of FC is critical for reduction in cellular CE content and, thus, reduction or reversal of plaque formation. Intracellular hydrolysis of CEs is the obligatory first step in this mobilization of cellular CEs, and we have earlier demonstrated that macrophage-specific transgenic expression of human CEH enhances macrophage CE mobilization and attenuates diet-induced atherosclerosis in LDLR −/− mice. 17 Cholesterol removed from arterial plaqueassociated macrophages returns to the liver and, whereas HDL-FC may be directly secreted into bile, 24 HDL-CEs need to be hydrolyzed within the hepatocyte, and uptake of CEs from HDL is efficiently coupled to bile acid synthesis. 25 The observed decrease in bile acid secretion and flux of labeled cholesterol from HDL to feces in liver-specific Ces3 deficiency clearly demonstrates the critical role of hepatic CE hydrolysis in regulating this last step in the process of RCT. It should be noted that the ability of primary hepatocytes to synthesize and secrete bile acids starting from [ 3 H]-cholesterol was not affected by Ces3 deficiency, indicating that decreased availability of FC attributable to Ces3 deficiency ( Figure VII in the online-only Data Supplement) is responsible for the observed reduction in the bile acid content of bile as well as flux of HDL-CEs to bile acids in the feces. These data are consistent with the reported increase in fecal bile acids by adenovirus-mediated CEH overexpression. 14 The flux of cholesterol from macrophage foam cells via plasma lipoproteins (eg, HDL) to liver and, finally, to feces is increasingly being considered more important than atherogenic lipoprotein profiles in determining the progression of atherosclerosis. Consistently, strategies aimed at enhancing the removal of cholesterol from macrophage foam cells (first step in RCT) lead to decrease in plaque burden or atherosclerosis in both mice 26, 27 and humans. 28 Similarly, enhancing the uptake of HDL-CEs by increasing hepatic SR-BI expression increased cholesterol elimination into feces (last step in RCT). 29 The data presented herein identify hepatic CE hydrolysis as another important step in the regulation of the last step in RCT, namely, the fecal elimination of total sterols (FC+bile acids).
Development of atherosclerosis is higher in male mice compared with females, and this sex difference is also observed in humans where the risk for the development of cardiovascular disease is lower in premenopausal women. Although treatment with estrogen 30 or estrogen-agonists 31 reduces atherosclerosis without affecting plasma lipids, the underlying mechanism(s) is not completely understood. Sex-specific differences in hepatic cholesterol content have recently been reported. 32 Several studies have demonstrated an increase in CEH activity by estradiol. [33] [34] [35] Chiba et al 36 suggested that estradioldependent activation of CEH is the underlying mechanism for the sex differences of atherogenesis in ApoE −/− mice. The magnitude of effects on reduction in bile acid content, flux of cholesterol from HDL-CEs to feces and, ultimately, development of atherosclerosis was higher in females than in males in the present study. Furthermore, significant sex effects were also noted in liver total cholesterol and CEs, plasma VLDL-C/ LDL-C, and fecal bile acids. It is also noteworthy that total bile acid synthesis as well as fecal bile acid excretion is higher in females and, using CYP7A1-deficient mice, Schwarz et al 37 demonstrated that this difference is attributable to classic bile acid synthetic pathway despite similar enzyme activity of CYP7A1 in the 2 sexes, suggesting a regulatory role of FC substrate availability. Taken together with these earlier studies, it is likely that in the absence of Ces3, the protection rendered by increased CE hydrolytic activity and resulting increased FC availability for bile acid synthesis is lost resulting in higher magnitude of differences in females. Additional studies in the future may completely establish whether hepatic CE hydrolysis represents the mechanism for the sex difference in susceptibility to atherosclerosis.
Mouse Ces3 is a member of carboxylesterase family, which includes enzymes with esterase activity toward a wide range of substrates and, therefore, members of this family have been named based on the first substrate used for characterization. Based on its initial characterization using TG as a substrate, Ces3 is also known as TG hydrolase (Tgh). Focusing on its role as a Tgh, Ces3 is thought to provide TG for VLDL assembly, and Wei et al 38 reported a decrease in plasma lipids in Tgh-deficient 129sv mice, and this decrease in plasma lipids (30% to 50%) was considered as the underlying mechanism for the observed decrease in atherosclerotic lesions in the aortic root of Tgh −/− LDLR −/− mice; development of lesions in the aorta/aortic arch was not examined in this study. 39 The data presented herein demonstrate an increase in atherosclerotic lesion in the entire aorta in LDLR −/− Ces3 −/− LKO mice and Ces3 deficiency-mediated inability to hydrolyze endogenous or lipoprotein-derived CEs and thereby reducing cholesterol elimination from the body was established as the underlying mechanism. It should be noted that Ces3 deficiency in the present study is liver specific. Intestinal deficiency of Ces3 in Tgh −/− Ldlr −/− mice led to a significant decrease in chylomicron secretion, 39 likely contributing to decrease in intestinal cholesterol absorption, which is shown to result in attenuated atherosclerosis in LDLR −/− mice. 40 In conclusion, the present study establishes the antiatherogenic role of hepatic CE hydrolysis, which is required for mobilizing endogenously synthesized or HDL-derived CEs to generate FC for biliary secretion and bile acid synthesis. Hepatic Ces3 deficiency decreased fecal elimination of cholesterol (as FC and bile acids) and thereby increased diet-induced atherosclerosis in LDLR −/− Ces3-LKO mice without affecting plasma lipid levels. Although modifying plasma lipoprotein profile and, specifically increase in HDL cholesterol, has been the focus of therapies targeted to reduce cardiovascular risk, recent developments, such as use of Niacin and cholesteryl ester transfer protein inhibitors, have clearly established the need for the change of paradigm from HDL cholesterol to HDL flux. 41 Therefore, demonstrating the role of hepatic Ces3 in modulating cholesterol flux from HDL to feces is significant.
Sources of Funding
This work was supported by National Institutes of Health grants HL 069946 and HL 097346 to S. Ghosh.
